Healthcare Industry News: PTC Therapeutics
News Release - April 21, 2006
PTC Therapeutics Announces Promotion of Claudia HirawatSOUTH PLAINFIELD, N.J., April 21 (HSMN NewsFeed) -- PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes, today announced the promotion of Claudia Hirawat to Senior Vice President of Corporate Development.
"I am extremely pleased to announce this promotion. Claudia has made significant contributions to our company, providing leadership across multiple areas including leading our efforts in establishing our business collaborations," commented Stuart Peltz, Ph.D., President and CEO of PTC Therapeutics, Inc.
Ms. Hirawat was most recently Vice President of Corporate Development at PTC. Her responsibilities focused on business development, public relations and advocacy group relations. In her new role as Senior Vice President of Corporate Development, Ms. Hirawat will focus on business development, advocacy group relations and commercial development.
Ms. Hirawat joined PTC in 2000 as the company's seventh employee. Prior to PTC, Ms. Hirawat was a Vice President at LedbetterStevens, a management consulting and senior-level retained search firm in New York focused exclusively in the biopharmaceutical area.
About PTC Therapeutics, Inc.
PTC is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, proprietary small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC has assembled proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities. PTC's current pipeline of clinical and preclinical product candidates addresses multiple indications, including genetic disorders, oncology, and infectious diseases.
Source: PTC Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.